Monopar Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Monopar Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11008
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Monopar Therapeutics Inc (Monopar) is a biopharmaceutical company that develops drugs and drug combinations to improve clinical outcomes for cancer patients. The company’s pipeline product includes huATN-658, a humanized monoclonal antibody for the potential treatment of various cancers including pancreatic cancer, ovarian cancer, and others. Its huATN-658 targets the urokinase plasminogen activator receptor. Monopar builds development pipeline through the licensing or acquisition of orphan oncology therapeutics at the preclinical through advanced clinical development stage. The company’s lead drug product candidate enters into clinical development through collaboration with research center in the UK. Monopar is headquartered in Wilmette, Illinois, the US.

Monopar Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Monopar Therapeutics Acquires GPX-150 from Gem Pharma 10
Venture Financing 11
Monopar Therapeutics Raises USD9.7 Million in Venture Financing 11
Monopar Therapeutics to Raise USD4.5 Million in Venture Financing 12
Monopar Therapeutics to Raise USD3 Million Financing 13
Monopar Therapeutics Raises USD2.1 Million Financing 14
Partnerships 15
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 15
Licensing Agreements 16
Monopar Therapeutics Enters into Licensing Agreement with Onxeo 16
Monopar Therapeutics Inc – Key Competitors 17
Monopar Therapeutics Inc – Key Employees 18
Monopar Therapeutics Inc – Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Monopar Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Monopar Therapeutics Acquires GPX-150 from Gem Pharma 10
Monopar Therapeutics Raises USD9.7 Million in Venture Financing 11
Monopar Therapeutics to Raise USD4.5 Million in Venture Financing 12
Monopar Therapeutics to Raise USD3 Million Financing 13
Monopar Therapeutics Raises USD2.1 Million Financing 14
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 15
Monopar Therapeutics Enters into Licensing Agreement with Onxeo 16
Monopar Therapeutics Inc, Key Competitors 17
Monopar Therapeutics Inc, Key Employees 18

List of Figures
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Monopar Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Monopar Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Public Power Corporation S.A.:企業の戦略・SWOT・財務情報
    Public Power Corporation S.A. - Strategy, SWOT and Corporate Finance Report Summary Public Power Corporation S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • KeyCorp (KEY):電力:M&Aディール及び事業提携情報
    Summary KeyCorp (KeyCorp) is a bank holding company that offers a range of retail and commercial banking, consumer finance, commercial mortgage and special servicing, commercial leasing, investment management, and investment banking products and services through its principle subsidiary, KeyBank Nat …
  • Alnylam Pharmaceuticals Inc (ALNY)-製薬・医療分野:企業M&A・提携分析
    Summary Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiova …
  • Channel Four Telivision Corp:企業の戦略的SWOT分析
    Channel Four Telivision Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • United Microelectronics Corporation (2303):企業の財務・戦略的SWOT分析
    United Microelectronics Corporation (2303) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Delcath Systems Inc (DCTH):医療機器:M&Aディール及び事業提携情報
    Summary Delcath Systems Inc (Delcath) specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloods …
  • Exelon Corporation:発電所・企業SWOT分析
    Exelon Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Sound Energy plc (SOU):企業の財務・戦略的SWOT分析
    Summary Sound Energy Plc (Sound Energy), formerly Sound Oil plc is an upstream oil and gas company that offers exploration and development of oil and gas properties in Europe and Africa. The company holds interests, owns, and operates the Badile permit located in the Piedmont Lombard Basin in northe …
  • AMETEK Inc (AME)-医療機器分野:企業M&A・提携分析
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturing company that manufactures electronic instruments and electromechanical devices. The company's products include medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titanium alloys …
  • Glaukos Corp (GKOS):企業の財務・戦略的SWOT分析
    Summary Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such …
  • Central Petroleum Ltd (CTP):企業の財務・戦略的SWOT分析
    Summary Central Petroleum Ltd (CPL) operates as an oil and gas company that offers exploration and development services. The company develops, produces, processes and markets hydrocarbons. It operates its oil and gas assets in Amadeus basin, Pedirka basin, Georgina basin, and Wiso basin. CPL’s Amade …
  • IRLAB Therapeutics AB (IRLAB A):製薬・医療:M&Aディール及び事業提携情報
    Summary IRLAB Therapeutics AB (IRL) is a pharmaceutical company that discovers and develops drugs to treat central nervous system associated diseases. The company conducts flagship technology integrative screening process, a phenotypic screening and systems pharmacology process is used for developme …
  • ERHC Energy Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary ERHC Energy Inc (ERHC Energy) is an exploration and production company that explores oil and gas assets. The company possesses deep water oil and gas exploration and production interests in the Gulf of Guinea and onshore interests in Republic of Chad and Republic of Kenya. It holds interests …
  • Akari Therapeutics Plc (AKTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a …
  • Dialog Group Bhd (DIALOG):企業の財務・戦略的SWOT分析
    Dialog Group Bhd (DIALOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Premier Gold Mines Limited:企業のM&A・事業提携・投資動向
    Premier Gold Mines Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Premier Gold Mines Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Oncodesign SA (ALONC):企業の財務・戦略的SWOT分析
    Summary Oncodesign SA (Oncodesign) is a biopharmaceutical company, specializing in precision medicine offers drug discovery and pharmacological evaluation services for cancer. Its service offerings include integrated drug discovery; metabolic and pharmacokinetic characteristics of chemical and biolo …
  • Neftisa:石油・ガス:M&Aディール及び事業提携情報
    Summary Neftisa is an upstream oil and gas company. The company's activities include prospecting and development of hydrocarbon reservoirs, oil production, gas condensate recovery, conversion of oil associated gas, oil-and-gas fields development and extraction, maintenance and monitoring of oil serv …
  • Apollo Education Group, Inc.:企業の戦略・SWOT・財務分析
    Apollo Education Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Apollo Education Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Nanobiotix SA (NANO):企業の製品パイプライン分析
    Summary Nanobiotix SA (Nanobiotix) designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, pancreatic, liver, rectal, prostate, head and neck cancers; Non-small cell lung cancer (NSCLC); recurrent he …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆